Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

net loss per share allocable to common stockholders, basic and diluted 74,189 73,605 Arena Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet Data (In thousands) March 31, December 31, 2009 2008 (unaudited) (Note) Assets Cash, cash equivalents and short-term investments $70,257 $110,129 Accounts receivable 1,795 1,823 Other current assets 3,898 5,031 Land, property and equipment, net 99,028 102,740 Acquired technology and other non-current assets 20,533 21,608 Total assets $195,511 $241,331 Liabilities and Stockholders' Equity Accounts payable, accrued liabilities and warrant liability $39,315 $46,789 Total deferred revenues 4,049 4,049 Total lease financing obligations and other long-term liabilities 87,155 72,861 Total stockholders' equity 64,992 117,632 Total liabilities and stockholders' equity $195,511 $241,331

Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... 14 At the Board of Directors,meeting held ... of,$.115 per share. The dividend is payable on ... 31, 2007. About Sigma-Aldrich: Sigma-Aldrich is a ... and organic chemical products and kits,are used in ...
... Summertime equals fun for a lot of,folks. But ... typical,summer fare could also mean aggravating their sensitive ... IBS," has more on,what people with IBS can ... from,ruining their celebrations. Listen to this report ...
... 15 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: SHPGY, ... the waiting period under,Hart-Scott-Rodino Antitrust Improvements Act of ... (human TGF BETA 3) from Renovo Group plc,(LSE: ... with its terms, the,License Agreement became effective on ...
Cached Biology Technology:Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3
(Date:9/16/2014)... impact that spelled doom for the dinosaurs 66 million ... to a much greater extent than their deciduous peers, ... results are published in the journal PLOS Biology ... trove of thousands of fossilized leaves of angiosperms ... able to reconstruct the ecology of a diverse plant ...
(Date:9/16/2014)... a new football season and another commercial cargo flight ... spacecraft is scheduled to blast off to the orbital ... company,s fourth contracted mission to the complex. , Included ... research investigations sponsored by the Center for the Advancement ... managing the U.S. National Laboratory on the space station, ...
(Date:9/16/2014)... Keystone XL pipeline (KXL) would likely increase oil sands ... surveyed by the non-profit organization Near Zero. The results ... Impact," and includes both supporters and opponents of the ... sands could lead to significantly higher greenhouse gas emissions, ... respond. , "This report examines three main scenarios ...
Breaking Biology News(10 mins):Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... has identified a genetic variant that substantially increases the ... populations. The study, published by Cell Press on August ... , associates a deletion on chromosome 3 with increased ... that affects 1% of the world population. Characterized by ...
... scientists have been able to measure the amount of water that ... result -- 285 billion metric tons, or 285 cubic kilometers of ... over half the volume of Lake Erie, which is the world,s ... of the water flowing through the Amazon River every year, and ...
... Swine Flu. Rabies. These are emerging infectious diseases where ... another and now infect humans. This is a phenomenon ... to determine what drives it. Gary McCracken, a ... head in Ecology and Evolutionary Biology, is one of ...
Cached Biology News:Large risk schizophrenia marker revealed 2First satellite measurement of water volume in Amazon floodplain 2First satellite measurement of water volume in Amazon floodplain 3UT professor uncovers clues into how viruses jump from hosts 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: